Biogen Q2 revenue $2.7B (+3% YoY); GAAP EPS $0.66, Non-GAAP $3.60; Growth Portfolio up 24% to $1.06B

BIOGEN INC.

Total revenue $2.7B (+3% YoY); GAAP diluted EPS $0.66 (down 85%), Non-GAAP diluted EPS $3.60 (down 34%).
Growth Portfolio revenue $1.06B (+24% YoY); SPINRAZA $402M (+2%), LEQEMBI in-market $184M (+15%), SKYCLARYS $168M (+29%).
Apellis acquisition closed May 14; SYFOVRE $162M (Biogen $97M), EMPAVELI $46M (Biogen $30M); $0.85 dilution to Non-GAAP EPS in 2026, accretive 2027.
Pipeline: litifilimab SLE data by end-2026; diranersen proof-of-concept in Alzheimer's; pending RayThera acquisition.
Full year 2026 guidance updated reflecting stronger underlying business outlook adjusted for transactions and milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.